Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 3
1992 1
1994 2
1995 2
1996 2
2001 3
2002 2
2003 1
2004 1
2006 1
2007 3
2008 1
2010 5
2011 2
2013 2
2014 2
2015 3
2016 3
2017 2
2018 3
2019 1
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
Innovation in the pharmaceutical industry: New estimates of R&D costs.
DiMasi JA, Grabowski HG, Hansen RW. DiMasi JA, et al. J Health Econ. 2016 May;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012. Epub 2016 Feb 12. J Health Econ. 2016. PMID: 26928437
Assessing Pharmaceutical Research and Development Costs.
DiMasi JA. DiMasi JA. JAMA Intern Med. 2018 Apr 1;178(4):587. doi: 10.1001/jamainternmed.2017.8703. JAMA Intern Med. 2018. PMID: 29610869 No abstract available.
Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA, Feldman L, Seckler A, Wilson A. DiMasi JA, et al. Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3. Clin Pharmacol Ther. 2010. PMID: 20130567 Review.
The cost of drug development.
DiMasi JA, Grabowski HG, Hansen RW. DiMasi JA, et al. N Engl J Med. 2015 May 14;372(20):1972. doi: 10.1056/NEJMc1504317. N Engl J Med. 2015. PMID: 25970070 No abstract available.
The price of innovation: new estimates of drug development costs.
DiMasi JA, Hansen RW, Grabowski HG. DiMasi JA, et al. J Health Econ. 2003 Mar;22(2):151-85. doi: 10.1016/S0167-6296(02)00126-1. J Health Econ. 2003. PMID: 12606142
Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases.
DiMasi JA, Florez MI, Stergiopoulos S, Peña Y, Smith Z, Wilkinson M, Getz KA. DiMasi JA, et al. Clin Pharmacol Ther. 2020 Feb;107(2):324-332. doi: 10.1002/cpt.1627. Epub 2019 Oct 11. Clin Pharmacol Ther. 2020. PMID: 31502248
Investigating investment in biopharmaceutical R&D.
Carter PH, Berndt ER, DiMasi JA, Trusheim M. Carter PH, et al. Among authors: dimasi ja. Nat Rev Drug Discov. 2016 Oct;15(10):673-4. doi: 10.1038/nrd.2016.104. Epub 2016 Sep 12. Nat Rev Drug Discov. 2016. PMID: 27616295 Free PMC article.
Assessing the Financial Benefits of Faster Development Times: The Case of Single-source Versus Multi-vendor Outsourced Biopharmaceutical Manufacturing.
DiMasi JA, Smith Z, Getz KA. DiMasi JA, et al. Clin Ther. 2018 Jun;40(6):963-972. doi: 10.1016/j.clinthera.2018.04.011. Epub 2018 May 11. Clin Ther. 2018. PMID: 29755005
Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.
Stergiopoulos S, Calvert SB, Brown CA, Awatin J, Tenaerts P, Holland TL, DiMasi JA, Getz KA. Stergiopoulos S, et al. Among authors: dimasi ja. Clin Infect Dis. 2018 Jan 6;66(1):72-80. doi: 10.1093/cid/cix726. Clin Infect Dis. 2018. PMID: 29020279 Free PMC article. Clinical Trial.
Competitiveness in follow-on drug R&D: a race or imitation?
DiMasi JA, Faden LB. DiMasi JA, et al. Nat Rev Drug Discov. 2011 Jan;10(1):23-7. doi: 10.1038/nrd3296. Epub 2010 Dec 10. Nat Rev Drug Discov. 2011. PMID: 21151030 Review.
47 results
Jump to page
Feedback